what do the elm-2 results tell us about the efficacy of odronextamab for r/r dlbcl?
Published 1 year ago • 123 plays • Length 1:51Download video MP4
Download video MP3
Similar videos
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
1:51
efficacy of odronextamab in r/r dlbcl & determining the optimal sequencing of immune therapies
-
2:01
elm-2 trial: using ctdna and mrd to measure odronextamab outcomes in dlbcl and fl
-
4:10
understanding prognosis: diving out of the dark
-
5:36
investigating epcoritamab for follicular lymphoma and beyond with reid merryman, md
-
53:58
new options when diffuse large b cell lymphoma (dlbcl) doesn’t respond to treatment
-
24:24
double-hit dlbcl
-
29:00
dlbcl in 2023: top docs discuss the latest in diffuse large b-cell lymphoma | treatments & research
-
3:26
phase ii study of acalabrutinib, lenalidomide & rituximab for high tumor burden follicular lymphoma
-
4:31
updates in bispecifics for dlbcl from ash: glofitamab, odronextamab, epcoritamab & mosunetuzumab
-
2:14
how does biomarker testing impact dlbcl treatment options?
-
1:24:16
perspectives on novel antibody platforms in dlbcl
-
13:46
understanding follicular lymphoma with sarah rutherford, md
-
6:45
differential diagnosis for follicular lymphoma
-
1:42
precision medicine for b-cell lymphomas
-
16:21
should r-chop remain the standard of care for dlbcl?
-
6:37
l-mind trial in relapsed/refractory dlbcl
-
20:02
what are the hurdles to using cell of origin in classification to treat dlbcl?
-
7:44
iwnhl 2015 roundtable: day 2 highlights – ibrutinib for diffuse large b-cell lymphoma